(HALO) Halozyme Therapeutics - Overview
Sector: Healthcare | Industry: Biotechnology | Exchange: NASDAQ (USA) | Market Cap: 7.893m USD | Total Return: 19.1% in 12m
Avg Turnover: 124M
EPS Trend: 87.8%
Qual. Beats: 0
Rev. Trend: 98.5%
Qual. Beats: 1
Warnings
Choppy Below Avwap Earnings
Tailwinds
No distinct edge detected
Halozyme Therapeutics, Inc. is a biopharmaceutical company specializing in the development and commercialization of drug-delivery technologies. The company’s core business model centers on its proprietary recombinant human hyaluronidase enzyme (rHuPH20), which modifies subcutaneous tissue to enhance the absorption of injected biologics and small molecules. This technology allows for the conversion of intravenous treatments into subcutaneous injections, reducing administration time for patients and healthcare providers.
The company operates primarily through a high-margin licensing and royalty model, partnering with major pharmaceutical firms including Roche, Pfizer, and Bristol Myers Squibb. By integrating rHuPH20 into existing blockbuster drugs like Darzalex and Herceptin, Halozyme generates recurring revenue streams tied to the commercial success of its partners portfolios. In the biotechnology sector, this platform-based approach often provides more diversified revenue compared to traditional single-molecule drug developers.
Halozyme’s portfolio includes internal products such as XYOSTED for testosterone replacement and Hylenex for fluid dispersion. Its collaborative pipeline spans oncology, immunology, and neuroscience, utilizing automated injector devices to expand the delivery options for complex monoclonal antibodies. For a deeper look into the companys valuation metrics and financial health, you may find further insights on ValueRay.
- ENHANZE royalty revenue growth from subcutaneous Darzalex and Phesgo market adoption
- Patent expiration timelines for core rHuPH20 technology impact long-term licensing income
- Expansion of partner pipeline through new subcutaneous delivery collaboration agreements
- Regulatory approval milestones for high-volume subcutaneous formulations of oncology biologics
- Capital allocation strategy including share buybacks and strategic mergers and acquisitions
| Net Income: 348.8m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.25 > 0.02 and ΔFCF/TA 2.41 > 1.0 |
| NWC/Revenue: 42.42% < 20% (prev 102.5%; Δ -60.11% < -1%) |
| CFO/TA 0.25 > 3% & CFO 677.4m > Net Income 348.8m |
| Net Debt (1.83b) to EBITDA (960.6m): 1.90 < 3 |
| Current Ratio: 2.76 > 1.5 & < 3 |
| Outstanding Shares: last quarter (122.9m) vs 12m ago -2.98% < -2% |
| Gross Margin: 76.93% > 18% (prev 80.17%; Δ -3.24% > 0.5%) |
| Asset Turnover: 61.96% > 50% (prev 49.36%; Δ 12.59% > 0%) |
| Interest Coverage Ratio: 44.97 > 6 (EBIT TTM 859.3m / Interest Expense TTM 19.1m) |
| A: 0.24 (Total Current Assets 1.00b - Total Current Liabilities 363.2m) / Total Assets 2.67b |
| B: 0.08 (Retained Earnings 204.8m / Total Assets 2.67b) |
| C: 0.35 (EBIT TTM 859.3m / Avg Total Assets 2.43b) |
| D: 0.09 (Book Value of Equity 219.6m / Total Liabilities 2.45b) |
| Altman-Z'' = 4.29 = AA |
| DSRI: 1.08 (Receivables 458.0m/304.6m, Revenue 1.51b/1.08b) |
| GMI: 1.04 (GM 80.17% / 76.93%) |
| AQI: 1.51 (AQ_t 0.59 / AQ_t-1 0.39) |
| SGI: 1.39 (Revenue 1.51b / 1.08b) |
| TATA: -0.12 (NI 348.8m - CFO 677.4m) / TA 2.67b) |
| Beneish M = -2.35 (Cap -4..+1) = BBB |
As of June 03, 2026, the stock is trading at USD 66.28 with a total of 1,740,936 shares traded.
Over the past week, the price has changed by -3.55%,
over one month by +2.65%,
over three months by -5.11% and
over the past year by +19.12%.
Halozyme Therapeutics has received a consensus analysts rating of 3.63. Therefore, it is recommended to hold HALO.
- StrongBuy: 2
- Buy: 2
- Hold: 3
- Sell: 1
- StrongSell: 0
| Analysts Target Price | 83.9 | 26.6% |
P/E Trailing = 23.3474
P/E Forward = 9.2166
P/S = 5.2322
P/B = 35.9345
P/EG = -2.5
Revenue TTM = 1.51b USD
EBIT TTM = 859.3m USD
EBITDA TTM = 960.6m USD
Long Term Debt = 1.94b USD (from longTermDebt, last quarter)
Short Term Debt = 208.7m USD (from shortTermDebt, last quarter)
Debt = 2.15b USD (from shortLongTermDebtTotal, last quarter) + Leases 2.55m
Net Debt = 1.83b USD (calculated: Debt 2.15b - CCE 318.6m)
Enterprise Value = 9.72b USD (7.89b + Debt 2.15b - CCE 318.6m)
Interest Coverage Ratio = 44.97 (Ebit TTM 859.3m / Interest Expense TTM 19.1m)
EV/FCF = 14.56x (Enterprise Value 9.72b / FCF TTM 667.7m)
FCF Yield = 6.87% (FCF TTM 667.7m / Enterprise Value 9.72b)
FCF Margin = 44.26% (FCF TTM 667.7m / Revenue TTM 1.51b)
Net Margin = 23.13% (Net Income TTM 348.8m / Revenue TTM 1.51b)
Gross Margin = 76.93% ((Revenue TTM 1.51b - Cost of Revenue TTM 348.0m) / Revenue TTM)
Gross Margin QoQ = 71.13% (prev 77.39%)
Tobins Q-Ratio = 3.64 (Enterprise Value 9.72b / Total Assets 2.67b)
Interest Expense / Debt = 0.89% (Interest Expense 19.1m / Debt 2.15b)
Taxrate = 30.70% (154.5m / 503.4m)
NOPAT = 595.5m (EBIT 859.3m * (1 - 30.70%))
Current Ratio = 2.76 (Total Current Assets 1.00b / Total Current Liabilities 363.2m)
Debt / Equity = 9.78 (Debt 2.15b / totalStockholderEquity, last quarter 219.6m)
Debt / EBITDA = 1.90 (Net Debt 1.83b / EBITDA 960.6m)
Debt / FCF = 2.74 (Net Debt 1.83b / FCF TTM 667.7m)
Total Stockholder Equity = 276.3m (last 4 quarters mean from totalStockholderEquity)
RoA = 14.33% (Net Income 348.8m / Total Assets 2.67b)
RoE = 126.3% (Net Income TTM 348.8m / Total Stockholder Equity 276.3m)
RoCE = 38.84% (EBIT 859.3m / Capital Employed (Equity 276.3m + L.T.Debt 1.94b))
RoIC = 24.38% (NOPAT 595.5m / Invested Capital 2.44b)
WACC = 5.34% (E(7.89b)/V(10.0b) * Re(6.62%) + D(2.15b)/V(10.0b) * Rd(0.89%) * (1-Tc(0.31)))
Discount Rate = 6.62% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -76.83 | Cagr: -3.74%
[DCF] Terminal Value 77.97% ; FCFF base≈598.9m ; Y1≈686.5m ; Y5≈1.01b
[DCF] Fair Price = 112.8 (EV 15.2b - Net Debt 1.83b = Equity 13.4b / Shares 118.6m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: 87.81 | EPS CAGR: 31.30% | SUE: -0.58 | # QB: 0
Revenue Correlation: 98.51 | Revenue CAGR: 28.07% | SUE: 1.07 | # QB: 1
EPS current Quarter (2026-06-30): EPS=1.82 | Chg30d=-0.02% | Revisions=-11% | Analysts=6
EPS next Quarter (2026-09-30): EPS=2.18 | Chg30d=-0.97% | Revisions=-11% | Analysts=6
EPS current Year (2026-12-31): EPS=8.14 | Chg30d=+0.66% | Revisions=+25% | GrowthEPS=+96.2% | GrowthRev=+27.2%
EPS next Year (2027-12-31): EPS=9.89 | Chg30d=+0.31% | Revisions=+25% | GrowthEPS=+21.5% | GrowthRev=+12.5%
[Analyst] Revisions Ratio: +25%